Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:56:06.243Z.
Consensus retrieved: 2026-10-06T10:02:54.739Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:56:06.243Z.
Quote observation: 2026-10-06T16:54:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c0c25a561797b8251bbc96a681ec43d66f95a8f813bb62f19698de697ac6593e
Forward PE Ratio (N/A) = Dated Quote Price ($1.75) / Consensus Forward EPS ($-2.75)
FORWARD PE RATIO
N/A
Celularity Inc.
Market Cap
$50.66M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Celularity Inc. (CELU) | $50.66M | N/A |
| Apollomics, Inc. (APLM)vs › | $50.73M | N/A |
| Clene Inc. (CLNN)vs › | $50.54M | N/A |
| INmune Bio, Inc. (INMB)vs › | $50.51M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.45M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $50.11M | N/A |
| Microbot Medical Inc. (MBOT)vs › | $50.08M | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.38M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.75 | $-2.75 – $-2.75 | 1 | n/m |
| 2027-12-31 | $1.50 | $1.50 – $1.50 | 1 | 1.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
